AMPK is a metabolic sensor that helps maintain cellular energy homeostasis. Despite evidence linking AMPK with tumor suppressor functions, the role of AMPK in tumorigenesis and tumor metabolism is unknown. Here we show that AMPK negatively regulates aerobic glycolysis (the Warburg effect) in cancer cells and suppresses tumor growth in vivo. Genetic ablation of the a1 catalytic subunit of AMPK accelerates Myc-induced lymphomagenesis. Inactivation of AMPKa in both transformed and nontransformed cells promotes a metabolic shift to aerobic glycolysis, increased allocation of glucose carbon into lipids, and biomass accumulation. These metabolic effects require normoxic stabilization of the hypoxia-inducible factor-1a (HIF-1a), as silencing HIF-1a reverses the shift to aerobic glycolysis and the biosynthetic and proliferative advantages conferred by reduced AMPKa signaling. Together our findings suggest that AMPK activity opposes tumor development and that its loss fosters tumor progression in part by regulating cellular metabolic pathways that support cell growth and proliferation.
INTRODUCTION
Genetic lesions that drive cancer progression affect key biological control points, including cell-cycle entry, DNA damage checkpoints, and apoptosis. However, the initiation of uncontrolled proliferation also presents a significant bioenergetic challenge to cancer cells; they must generate enough energy and acquire or synthesize biomolecules at a sufficient rate to meet the demands of proliferation. It is now appreciated that many of the predominant mutations observed in cancer also control tumor cell metabolism (Levine and Puzio-Kuter, 2010) , suggesting that oncogene and tumor suppressor networks influence metabolism as part of their mode of action. One of the primary metabolic changes observed in proliferating cells is increased catabolic glucose metabolism. Many tumor cells adopt a metabolic phenotype characterized by high rates of glucose uptake and lactate production regardless of oxygen concentration, a phenomenon commonly referred to as the ''Warburg effect'' (Vander Heiden et al., 2009) . While the energetic yield per molecule of glucose is much lower for aerobic glycolysis compared to oxidative phosphorylation (OXPHOS), the metabolic shift toward the Warburg effect appears to confer both bioenergetic and biosynthetic advantages to proliferating cells by promoting increased nonoxidative ATP production and generating metabolic intermediates from glucose that are important for cell growth (DeBerardinis et al., 2008) .
Appreciation of the generality of the Warburg effect in cancer has stimulated the broader concept that a ''metabolic transformation'' accompanies tumorigenesis (Jones and Thompson, 2009 ). However, the metabolic control points and signal transduction pathways that regulate the Warburg effect during tumorigenesis and their importance to tumor progression in vivo remain poorly defined. The AMP-activated protein kinase (AMPK) is a highly conserved Ser/Thr protein kinase complex that plays a central role in the regulation of cellular energy homeostasis. AMPK is activated in response to declining fuel supply and functions in the decision to allocate nutrients toward catabolic/energy-producing or anabolic/growth-promoting metabolic pathways (Hardie, 2011) . From a metabolic standpoint, AMPK promotes ATP conservation under conditions of metabolic stress by activating pathways of catabolic metabolism such as autophagy (Egan et al., 2011; Kim et al., 2011) and inhibiting anabolic processes including lipid biosynthesis (Davies et al., 1990) , TORC1-dependent protein biosynthesis (Gwinn et al., 2008; Inoki et al., 2003) , and cell proliferation (Imamura et al., 2001; Jones et al., 2005) . AMPK activity has been recently linked to stress resistance and survival in tumor cells (Jeon et al., 2012; Liu et al., 2012) .
Due to its involvement in cellular stress resistance, AMPK has been linked to the regulation of tumorigenesis ). The upstream AMPK-activating kinase LKB1 is a tumor suppressor gene inactivated in patients with PeutzJegher's syndrome (Alessi et al., 2006) , a condition that predisposes patients to gastrointestinal polyps and malignant tumors (Giardiello et al., 1987; Hearle et al., 2006) . Cells lacking LKB1 display defective energy-dependent AMPK activation (Hawley et al., 2003; Shaw et al., 2004b) . Additional evidence supporting a tumor suppressor function for AMPK is derived from experiments with the glucose-lowering drug metformin, which acts in part by activating AMPK (Zhou et al., 2001) . Treatment of animals harboring tumor xenografts or naturally arising lymphomas with metformin can delay tumor progression (Buzzai et al., 2007; Huang et al., 2008) . However, to date the role of AMPK in tumorigenesis and tumor metabolism has remained unclear.
In this work, we demonstrate that loss of AMPK signaling cooperates with Myc to accelerate tumorigenesis. Moreover, silencing AMPKa in both transformed and nontransformed cells results in a switch to aerobic glycolysis (Warburg effect) in the absence of energetic crisis. This metabolic shift is characterized by increased glucose uptake, redirection of carbon flow toward lactate, increased flux of glycolytic intermediates toward lipid biosynthesis, and an increase in net biomass (size). Induction of this metabolic shift is dependent on HIF-1a, as silencing of HIF-1a by shRNA ablates the effects of AMPKa loss on aerobic glycolysis, biosynthesis, and tumor growth in vivo. Our findings indicate that AMPK is a metabolic sensor essential for the coordination of metabolic activities that support cell growth and proliferation in cancer cells, and that disruption of AMPK signaling promotes metabolic reprogramming of cancer cells to drive the Warburg effect and influence tumor development and progression in vivo.
RESULTS

Loss of AMPKa1
Accelerates Myc-Driven Lymphomagenesis AMPK lies downstream (Hawley et al., 2003; Shaw et al., 2004b) and upstream (Inoki et al., 2003) of known tumor suppressors (LKB1 and TSC2, respectively), but its role in tumorigenesis has remained unclear. To address this question, we generated Em-Myc transgenic mice (Adams et al., 1985) harboring a mutation in the gene that encodes AMPKa1 (prkaa1), which is the sole catalytic subunit expressed in B lymphocytes ( Figure S1A available online). Latency to tumor development was monitored by palpation, and both tumor-free survival and overall life span were monitored. Compared to Em-Myc control mice, Em-Myc animals lacking AMPKa1 displayed accelerated lymphomagenesis with a median tumor onset of 7 weeks ( Figure 1A ) and a maximum overall survival rate of 20 weeks ( Figure S1B ). Em-Myc mice heterozygous for AMPKa1 displayed an intermediate phenotype, with a median tumor onset of 10 weeks (Figure 1A) . Lymph node tumors isolated from Em-Myc/a1
+/+ and Em-Myc/a1 À/À mice displayed prominent B220/CD45R staining, indicating that tumors arising in these animals were of B cell origin ( Figure S1C) ; however, all AMPKa1-deficient B220 + lymphomas examined lacked surface immunoglobulin (sIg) expression, suggesting that these tumors were pre-B cell tumors, rather than mature B cell tumors ( Figure S1C ). To assess whether the accelerated tumor onset observed in Em-Myc/a1 À/À animals was due to a cell intrinsic effect of AMPKa1 deficiency in B cells, we generated chimeric mice using Em-Myc/a1 +/+ or Em-Myc/a1 À/À hematopoietic stem cells (HSCs) to reconstitute lethally irradiated wild-type mice (C57BL/6 background). All animals reconstituted with Em-Myc/a1 À/À HSCs developed palpable lymphomas within 9 weeks of reconstitution, while only 20% of animals receiving Em-Myc/a1 +/+ HSCs developed tumors 12 weeks after reconstitution ( Figure 1B ). These data establish that specific loss of AMPKa1 in B cells can promote accelerated Myc-driven lymphomagenesis. While lymph node tumors from both genotypes looked histologically similar by hematoxylin and eosin staining ( Figure S1D ), Em-Myc/a1 À/À lymphomas displayed increased proliferation marker Ki-67 staining in situ ( Figure 1C ). Immunohistochemical (IHC) analysis revealed no major differences in tumor vascularization (measured by CD31 staining) or apoptosis (IHC for cleaved caspase-3) between AMPKa1-deficient and control Em-Myc tumors ( Figure S1E ). We next silenced AMPKa1 in primary Em-Myc lymphoma cells using short hairpin RNA (shRNA; Figure S1F ) and measured the impact of AMPKa1 levels on cell proliferation using an in vitro competition assay. Primary Em-Myc lymphoma cells were transduced with retroviral vectors coexpressing GFP and control or AMPKa1-specific shRNAs, and the percentage of GFP + cells remaining after 6 days of culture was determined by flow cytometry. AMPKa1 shRNA-expressing cells displayed a competitive growth advantage in vitro over cells expressing control shRNA ( Figure 1D ).
Activation of AMPK promotes cell survival in response to metabolic stress (Bungard et al., 2010; Buzzai et al., 2007; Jeon et al., 2012) . To determine whether loss of AMPK renders Em-Myc tumors sensitive to metabolic stress, we treated Em-Myc lymphoma cells expressing control or AMPKa1 shRNAs with the glycolytic inhibitor 2-deoxyglucose (2-DG) and measured cell viability after 24 hr. AMPKa1 shRNA-expressing lymphomas displayed normal viability under standard growth conditions but increased cell death in the presence of 2-DG ( Figure 1E ). Together, these data suggest that loss of AMPKa1 can enhance tumor development driven by oncogenic Myc in vivo but is required to maintain tumor cell viability.
We next explored putative altered signaling events in AMPKa1-deficient lymphomas by IHC analysis of tumor sections. AMPKa, phospho-AMPKa, and phospho-ACC (pACC) expression in tumor-bearing lymph nodes confirmed a complete loss of AMPK signaling in Em-Myc/a1 À/À tumors (Figure S1G) . Similar to that observed in Lkb1 +/À tissues Shaw et al., 2004a) , tumor tissue from Em-Myc/a1 À/À mice displayed increased staining for S6 and 4E-BP1 phosphorylation ( Figure 1F ), suggesting an increase in basal TORC1 signaling in AMPKa-null lymphomas in vivo.
Similar data were observed via immunoblotting of primary lymphoma cells isolated immediately ex vivo from tumor-bearing lymph nodes. Both TORC1 and AMPK activity (as determined by ACC phosphorylation) were elevated in Em-Myc lymphoma cells compared to normal B cells ( Figure 1G ). When comparing EmMyc/a1 +/+ and Em-Myc/a1 À/À lymphomas directly, pACC levels were ablated in a1 À/À tumors, while TORC1 activity was increased in a1 À/À tumors with some variability in levels of both S6 and 4E-BP1 phosphorylation between a1 À/À tumor samples ( Figure 1G ).
Loss of AMPKa Signaling Enhances the Warburg Effect in Cancer Cells
AMPK sits at a central node in the regulation of catabolic and anabolic metabolism (Hardie et al., 2012 Figure S1 .
lymphoma cells using nuclear magnetic resonance (NMR) spectrometry. Employing a stringent statistical cutoff (p < 0.01) and metabolites displaying a 2-fold change in abundance, we identified 13 metabolites showing differential abundance in shAMPKa1 lymphoma cells (Figure 2A) . By these criteria, glucose was the only metabolite significantly decreased in shAMPKa1 lymphoma cells, while lactate displayed the greatest increase ( Figure 2A ). Lymphomas expressing AMPKa1 shRNA displayed an elevated extracellular acidification rate (ECAR, Figure 2B ), an index of lactate production (Wu et al., 2007) , but displayed no significant difference in their oxygen consumption rate (OCR; Figures 2C and S2A). AMPKa1 shRNA-expressing Em-Myc lymphoma cells also displayed increased glucose consumption ( Figure 2D ) and lactate production ( Figure 2E ) relative to control lymphoma cells, a metabolic signature consistent with the Warburg effect.
To assess whether reducing AMPK activity is sufficient to enhance the Warburg effect in cancer cells we silenced AMPK in two independent cell lines, H1299 (non-small-cell lung carcinoma) and HCT116 (colon carcinoma). Expression of shRNAs targeting both the a1 and a2 subunits of AMPK reduced total AMPKa protein expression in these cell lines (Figures 2F and 2G), and AMPKa silencing promoted a significant increase in the basal ECAR of both H1299 ( Figure 2H ) and HCT116 cells ( Figure 2I ). Lactate production was also elevated in H1299 and HCT116 cells expressing AMPKa shRNA (Figures S2B and S2C) . Taken together with our observations using AMPKa1 shRNA-expressing Em-Myc lymphoma cells, these data suggest that downregulation of AMPK signaling is sufficient to enhance the Warburg effect in transformed cells.
Loss of AMPK Signaling Promotes Increased ATP Levels and Anabolic Metabolism
Given the increased metabolic demands of cell proliferation, we hypothesized that an intact AMPK signaling pathway may function to coordinate metabolism and biosynthesis in actively dividing cells. To address this, we generated nontransformed mouse embryonic fibroblasts (MEFs) deficient for AMPKa. Using MEFs deficient for prkaa1 and harboring a conditional mutation for prkaa2 (denoted hereafter as a1
fl/fl ), we generated paired isogenic cell lines that possess or completely lack AMPK catalytic activity depending on expression of Cre recombinase ( Figure S3A ). MEFs lacking AMPKa (Cre+) displayed increased glucose consumption ( Figure S3B ), lactate production ( Figure S3C ), and ECAR ( Figure 3A ) relative to control (Cre-) cells. We next traced the metabolic fate of 13 C-glucose in these cells, and we found that AMPKa-deficient cells displayed a progressive increase in the m+3 isotopologue of lactate ( 13 C 3 -lactate) derived from glucose over time ( Figure 3B ), corresponding to a 6-fold increase in the glucose-to-lactate conversion rate. One possibility for the increased ECAR in cells lacking AMPK activity could be a compensatory response to low cellular energy triggered by AMPK loss. To address this, we measured the adenylate energy charge in unstressed, actively growing MEFs by high-performance liquid chromatography (HPLC). Remarkably, cellular ATP levels were elevated in AMPKa-deficient MEFs relative to controls ( Figure 3C ). In contrast, the AMP:ATP ratio was not significantly affected by the loss of AMPK activity in proliferating cells ( Figure 3D ), suggesting no significant change in basal cellular energy charge when AMPKa is absent.
The metabolic shift to the Warburg effect facilitates the redirection of glucose-derived carbon toward biosynthetic pathways to generate biomass (Vander Heiden et al., 2009) , including extrusion of glucose-derived citrate from the citric acid cycle (CAC) for lipid biosynthesis (Hatzivassiliou et al., 2005) . Consistent with this, total citrate levels were elevated in AMPKadeficient cells relative to control cells as determined by gas chromatography-mass spectrometry (GC-MS) ( Figure 3E ). We next measured glucose-dependent lipid biosynthesis by culturing MEFs with D-[6-14 C]-glucose, and we found that AMPKa-deficient cells displayed increased 14 C-labeling in lipids ( Figure 3F ). Decreased ACC phosphorylation in AMPKa-null cells is predicted to contribute to lipid synthesis, but it may also decrease fatty acid oxidation. Baseline palmitate oxidation remained low in proliferating cells grown under full glucose conditions regardless of AMPK expression ( Figure 3G ). However, cells expressing AMPKa shRNA displayed a reduced ability to oxidize lipid upon complete removal of glucose ( Figure 3G ), suggesting that AMPK is required to trigger catabolic lipid metabolism specifically under nutrient poor conditions. Consistent with shunting of glucose-derived carbon toward biosynthesis in proliferating cells, AMPKa-null MEFs displayed a 20% increase in median cell size as determined by forward scatter (FSC) with flow cytometry ( Figure 3H ). TORC1 is a central regulator of cell size (Laplante and Sabatini, 2009) , and AMPK can negatively regulate TORC1 activity under energy stress (Inoki et al., 2003; Shaw et al., 2004a) . Consistent with this, the AMPK agonist AICAR suppressed TORC1 activity (as determined by reduced pS6 and p4E-BP levels) only in cells with wild-type AMPKa ( Figure S3D) . Notably, growth factor-dependent TORC1 activity in cells was similar regardless of AMPKa status ( Figure S3E ), suggesting the existence of TORC1-independent pathways of biomass regulation in AMPKa-deficient cells.
Loss of AMPKa Promotes a Glycolytic Signature and Increased HIF-1a Expression
We next investigated potential mechanisms governing the glycolytic phenotype associated with AMPKa-deficient cells. We first used quantitative PCR (qPCR) to examine the relative levels of messenger RNA (mRNA) transcripts encoding for proteins involved in glycolytic regulation. AMPKa-null MEFs displayed a glycolytic gene signature marked by increased mRNA expression of Aldolase A (aldoa), Lactate dehydrogenase A (ldha), and pyruvate dehydrogenase kinase 1 (pdk1) ( Figures 4A and  S4A ), a pattern of gene expression also displayed by shAMPKa1 lymphoma cells ( Figure S4B ). Elevated Aldolase, LDHA, and PDK1 protein levels were also detected in AMPKa-deficient MEFs ( Figure 4B ) and shAMPKa1 lymphoma cells ( Figure 4C ).
PDK1 curbs pyruvate flux to Acetyl-CoA and entry into the TCA cycle by antagonizing the action of the pyruvate dehydrogenase (PDH) complex (Kim et al., 2006; Papandreou et al., 2006 Figure S4D) .
Several of the enzymes elevated in AMPKa-deficient cells are known targets of the transcription factor HIF-1a, one of the central regulators of glycolysis induced by hypoxia (Keith et al., 2012; Semenza, 2011) . We observed elevated HIF-1a protein levels under normoxia after acute AMPKa deletion in our isogenic cell lines ( Figure 4D Error bars represent the SEM. *p < 0.05, ***p < 0.001, ****p < 0.0001. See also Figure S3 and Table S1 .
lymphomas ( Figure 4E ) or HCT116 cells ( Figure 4F ) promoted normoxic HIF-1a protein stabilization. Levels of hif1a mRNA were unchanged in AMPKa null MEFs relative to controls (Figure 4G) , suggesting that reduction of AMPK activity is sufficient to increase HIF-1a protein levels in cancer cells under normoxic conditions independent of mRNA levels. TORC1 signaling has been linked to control of HIF-1a expression through differential regulation of its translation (Choo et al., 2008) . To examine the contribution of TORC1 signaling to HIF-1a stabilization in AMPKa-deficient cells, we silenced the TORC1 binding partner Raptor using small interfering RNA (siRNA). Treatment with Raptor siRNA significantly reduced hif1a mRNA levels in both control and AMPKa-deficient MEFs, with the latter demonstrating a large drop in hif1a mRNA expression upon Raptor depletion ( Figure 4H ). Moreover, transient knockdown of Raptor in AMPKa-deficient MEFs reduced HIF-1a protein levels ( Figure 4I ) and reduced the expression of the HIF-1a targets aldoa ( Figure S4E ) and ldha ( Figure S4F ).
AMPKa-Dependent Effects on Glycolysis Are Mediated by HIF-1a
To determine the contribution of HIF-1a to the glycolytic phenotype observed in AMPKa null cells, we stably silenced HIF-1a in control (Cre-) or AMPKa-deficient (Cre+) MEFs using RNA interference. Expression of HIF-1a shRNA ablated HIF-1a protein expression in AMPKa-deficient MEFs under normoxia ( Figure 5A ) and blocked CoCl 2 -dependent induction of HIF-1a protein in both AMPKa-deficient and control cells ( Figure S5A ). Expression of HIF-1a shRNA reduced pdk1 mRNA in AMPKanull cells to control levels, demonstrating that expression of this shRNA could block HIF-1a-dependent transcription (Figure 5B) . We next determined whether silencing HIF-1a could reverse the Warburg effect triggered by loss of AMPKa activity. While HIF-1a shRNA had little effect on the ECAR of control cells, silencing HIF-1a in AMPKa-deficient cells lowered the ECAR below control levels ( Figure 5C ). GC-MS analysis revealed dramatic reductions in intracellular pyruvate and lactate in AMPKa-deficient cells expressing HIF-1a shRNA relative to control shRNA ( Figure 5D ). Moreover, silencing of HIF-1a ablated the enhanced levels of glucose consumption ( Figure 5E ) and lactate production ( Figure 5F ) displayed by AMPKadeficient cells. Similar reductions in glucose consumption and lactate production were observed in AMPKa-deficient MEFs transfected with HIF-1a siRNA ( Figures S5B-S5D) . Silencing of Raptor in AMPKa-deficient MEFs, which partially reduced HIF-1a protein levels ( Figure 4I ), led to slight reductions in lactate production ( Figure S5E ) and ECAR ( Figure S5F ).
HIF-1a Drives Increased Biosynthesis in AMPKa-Null Cells
Next we determined the impact of HIF-1a expression on cellular biosynthesis and proliferation induced by AMPKa loss. Silencing of HIF-1a reduced intracellular citrate in AMPKa-deficient cells by approximately 70% (Figure 6A ), restoring citrate levels to that observed in control cells. Moreover, suppression of HIF-1a dramatically reduced glucose-dependent lipogenesis in AMPKa-deficient MEFs ( Figure 6B ). Suppression of HIF-1a had little effect on glucose-dependent lipogenesis in control cells ( Figure 6B) , consistent with the fact that HIF-1a protein is maintained at low levels in these cells under normoxia.
Given that aberrant HIF-1a expression drives both enhanced glycolysis and glucose-derived lipogenesis, we reasoned that the increased size of AMPKa-deficient cells may be attributed to HIF-1a-dependent changes in anabolic metabolism. While loss of AMPKa promotes increased cell size, silencing of HIF-1a restored the size of AMPKa-deficient MEFs to that of control cells ( Figure 6C) . Notably, rapamycin treatment also reduced the size of AMPKa-deficient MEFs ( Figure S6A ). However, this treatment also reduced hif1a mRNA levels in cells regardless of AMPKa expression ( Figure S6B ), suggesting that rapamycin may exert its effects in part through regulation of HIF-1a mRNA. Finally, suppression of HIF-1a signaling in AMPKa-deficient cells reduced their overall rate of proliferation ( Figure 6D ). Collectively, the data suggest that AMPK negatively regulates the metabolic (Warburg effect) and biosynthetic programs of proliferating cells through the inhibition of HIF-1a function.
HIF-1a Is Required for the Progression of AMPKa1-Deficient Lymphomas
Our earlier results (Figure 2 ) indicate that reduced AMPK signaling synergizes with Myc to promote the Warburg effect in lymphoma. To determine the contribution of HIF-1a to the glycolytic phenotype of Em-Myc lymphoma cells, we stably expressed HIF-1a-specific shRNAs in Em-Myc lymphoma cells with silenced AMPKa1. Silencing of HIF-1a in AMPKa1 shRNA-expressing cells reduced HIF-1a protein expression to control levels ( Figure 7A ). Protein levels of the HIF-1a targets Aldolase and LDHA expression also decreased when HIF-1a was silenced in AMPKa1 shRNA-expressing lymphomas (Figure 7A) . We next examined metabolic activity in these lymphomas. Expression of AMPKa1 shRNA increased cellular ECAR as expected, while silencing of HIF-1a reduced this enhanced ECAR response by 60% ( Figure 7B ). Finally, lymphoma cells expressing both AMPKa1 and HIF-1a shRNA showed decreased proliferation relative to cells expressing AMPKa1 shRNA alone ( Figure 7C ).
We next tested the requirement for HIF-1a for tumor progression in vivo. Primary control or AMPKa-deficient Em-Myc lymphoma cells were transduced with retroviral vectors expressing GFP and either control or HIF-1a shRNAs, and the percentage of GFP + lymphoma cells (expressing the shRNA of interest) was determined by flow cytometry prior to transplantation into recipient mice and after lymphoma formation ( Figure 7D ). Expression of control shRNA did not dramatically alter the fraction of GFP + Em-Myc lymphoma cells regardless of genotype (Figures 7E and 7F) . Interestingly, silencing of HIF1a in Em-Myc lymphomas promoted a general increase in the number of GFP + tumor cells, although this did not reach statistical significance ( Figure 7F ). However, lymphoma cells expressing HIF-1a shRNA were selectively depleted in AMPKa-null tumors ( Figures 7E and 7F) . Collectively, these data suggest that loss of AMPK signaling promotes a metabolic and growth advantage in lymphoma cells and that HIF-1a is required for the growth of AMPKa1 null tumors in vivo.
DISCUSSION
AMPK is a cellular energy sensor that coordinates metabolic activities in many tissues. Under conditions of energetic stress, AMPK activation suppresses cell growth and proliferation, leading to speculation that AMPK may function as part of a tumor suppressor pathway (Hardie, 2011; ). Here we provide genetic evidence that AMPKa displays tumor suppressor activity in vivo. Loss of AMPK signaling cooperates with oncogenic Myc to enhance tumorigenesis in a mouse model of lymphomagenesis, suggesting that AMPK may function as a tumor suppressor (Figure 1) . Moreover, we demonstrate that AMPK is a negative regulator of both aerobic glycolysis and cellular biosynthesis in cancer cells. Cells deficient for the catalytic alpha subunit(s) of AMPK display increased aerobic glycolysis marked by increased lactate production from glucose (Figures 2 and 3) , and downregulation of AMPK activity is sufficient to induce the Warburg Effect in cancer cells (Figure 2) . We find that HIF-1a is a key mediator of AMPK-dependent effects on cellular metabolism. Reduction of AMPKa levels in cells leads to increased HIF-1a protein levels under normoxia in both transformed and nontransformed cells (Figure 4) , and HIF-1a is required to drive both the Warburg effect and the growth of AMPKa1-deficient lymphomas in vivo ( Figure 5, 6, and 7) . The results presented here suggest that the downregulation of AMPK activity eliminates a key metabolic checkpoint that normally antagonizes anabolic progrowth cellular metabolism. Thus, AMPK may act in cancer cells as a metabolic gatekeeper that functions to establish metabolic checkpoints that limit cell division, and its loss of function can enhance both tumorigenesis and tumor progression.
All cells must manage their energetic resources to survive. We and others have established that AMPK is the central mediator of a metabolic cell-cycle checkpoint activated in response to nutrient limitation in mammalian cells (Gwinn et al., 2008; Inoki et al., 2003; Jones et al., 2005) . However, programs of ATP production and macromolecular synthesis must also be coordinated in proliferating cells to ensure proper cell division. The data presented here suggest that AMPK functions to regulate metabolic homeostasis in proliferating cells in the absence of acute energetic stress. Isogenic MEFs or cancer cells lacking AMPKa activity display a metabolic shift toward aerobic glycolysis, thus allowing cancer cells to engage aerobic glycolysis for ATP production and divert glucose-derived CAC intermediates toward lipid biosynthesis to support increased cell growth. AMPK may also influence lipid biosynthesis through regulation of ACC and other lipogenic enzymes, possibly through its effects on SREBP-1 (Li et al., 2011) . Thus, defective AMPKa signaling promotes the rewiring of metabolic pathways to favor cell growth pathways.
Interestingly our data provide evidence that AMPKa-deficient tumors display increased activation of the TORC1 targets S6 and 4E-BP1, suggesting that AMPK, as opposed to other AMPKrelated kinases, may be the key TORC1 regulator downstream of LKB1 in tumors. Consistent with past work (Inoki et al., 2003; Liu et al., 2006; Shaw et al., 2004a) , we find that AMPK functions to downregulate TORC1 activity specifically under conditions of energetic stress, when it is desirable to suppress ATP-consuming processes such as mRNA translation. This may provide a metabolic advantage to proliferating cells, where the loss of AMPK signaling promotes increased ATP production and resource accumulation without affecting the mitogenic properties of TORC1. By concurrently silencing AMPK while maintaining TORC1 signaling, cells may effectively bypass endogenous brakes on cellular metabolism, supporting increased tumor cell growth and proliferation.
Our work here establishes HIF-1a as a key mediator of the metabolic transformation triggered by reduced AMPKa activity in cancer cells. We show that downregulation of AMPK signaling is sufficient to induce normoxic HIF-1a stabilization and enhance the Warburg effect. TORC1 activity appears to contribute in part to this process, as silencing of the mTORC1 binding partner Raptor reduces levels of hif1a mRNA in AMPKa-deficient cells. However, silencing of Raptor moderately reduces HIF-1a protein levels and has a minimal effect on the glycolytic phenotype of AMPKa-deficient cells, suggesting that AMPK may regulate HIF-1a-dependent Warburg metabolism through additional mechanisms. Interestingly, TORC1 inhibition reduces hif1a mRNA and reduces glycolysis in cells regardless of AMPK expression, suggesting that TORC1 may function on a more global level as a positive regulator of glycolysis beyond specific effects on HIF-1a expression (Dü vel et al., 2010) . Given that TORC1 signaling is elevated in AMPKa1-deficient lymphomas, this may have implications for tumor metabolism in vivo. HIF-1a mRNA levels are unaffected by AMPK expression; thus, AMPK may affect normoxic HIF-1a protein expression either through decreased protein turnover or differential translation of HIF-1a mRNA (Choo et al., 2008) . Overall, we propose that AMPK functions to coordinate glycolytic and oxidative metabolism in proliferating cells by restricting HIF-1a function.
One consequence of AMPK loss in cells is enhanced flux of glucose-derived carbon to citrate for lipid biosynthesis, promoting biomass accumulation and increased cell size. This may appear to be counterintuitive, as HIF-1a-dependent upregulation of PDK1 under hypoxia is proposed to direct glucose-derived carbon away from the CAC (Kim et al., 2006; Papandreou et al., 2006) . However, glucose-to-citrate flux is not blocked in AMPKa-null cells, despite elevated PDK1 levels. Rather, the reduced levels of citrate(m+4) in AMPKa-null cells may result from increased use of glucose-derived citrate(m+2) for lipid biosynthesis. Reduction of AMPK levels significantly decreases ACC1 inhibition in both tumor cells and tumor tissue, which would permit maximal activity of ACC1 for lipid biosynthesis. Thus, AMPK may regulate lipid biosynthesis and biomass accumulation on multiple levels: substrate availability (HIF-1a-dependent glucose-derived citrate) and ACC activity.
We propose that AMPK may function as a metabolic tumor suppressor, limiting the growth of cancer cells by regulating key bioenergetic and biosynthetic pathways required to support unchecked proliferation. Thus, selection against AMPK activity may represent an important regulatory step for tumor initiation and progression, allowing tumor cells to gain a metabolic growth advantage. Reduced AMPK activity has been detected in primary human breast cancer (Hadad et al., 2009) , and reduced expression of prkaa2, the gene that encodes for AMPKa2, has been linked to human breast, ovarian, and gastric cancer (Hallstrom et al., 2008; Kim et al., 2012) . It is also well documented that LKB1 deficiency or genetic events that target LKB1 activity (Godlewski et al., 2010; Zheng et al., 2009) lead to reduced AMPK signaling in tumor cells. Thus, there may be several routes by which AMPK function is suppressed in tumors to provide a selective metabolic growth advantage. While selection for loss of AMPK function may favor the Warburg effect in tumor cells, it may also eliminate metabolic checkpoints essential for cellular adaptation to stress. AMPK normally plays a protective role to block cell growth in response to poor nutrient conditions, and as such its loss or suppression during tumorigenesis may sensitize tumor cells to apoptosis under hypoxic or nutrient depleted environments (Svensson and Shaw, 2012) . Consistent with this, silencing AMPKa1 in EmMyc lymphomas conferred sensitivity to apoptosis induced by the glycolytic inhibitor 2-DG. The increased levels of ACC phosphorylation observed in Em-Myc tumors (Figure 1 ) imply that lymphomas experience metabolic stress and AMPK activation in vivo. Thus, while ablation of AMPK signaling may enhance tumorigenesis, inhibition of this central energy-sensing pathway may offer unique a therapeutic window for the treatment of tumors with metabolic inhibitors. Our data provide a mechanistic rationale in support of the use of AMPK agonists such as metformin for cancer therapy (Buzzai et al., 2007; Evans et al., 2005) , as the efficacy of these agents against tumor growth may lie in their ability to engage AMPK-dependent metabolic checkpoints to restrict anabolic growth. Understanding the reprogramming of cellular metabolic networks by AMPK in cancer may aid in the development of novel approaches for cancer therapy. ) were generated by timed mating as previously described (Jones et al., 2005) and immortalized with SV40 Large T Antigen. HCT116 cells were obtained from ATCC. Primary Em-Myc lymphoma cells were provided by Jerry Pelletier (Robert et al., 2009) . DNA plasmids MiCD8t, pKD-HIF-1a hp, and LMP-based shRNAs against mouse and human AMPKa1 and a2 have been described previously (Bungard et al., 2010; Jones et al., 2005; Lum et al., 2007) . AMPKa-deficient MEFs were generated by transduction of a1
fl/fl MEFs with Cre-expressing retrovirus to delete a2-floxed alleles. For siRNA transfections, cells were subjected to two rounds of reverse transfection with pooled siRNAs against HIF1a (Dharmacon) with Lipofectamine RNAimax (Hatzivassiliou et al., 2005 Immunoblotting Cells were lysed in modified CHAPS buffer (10 mM Tris-HCl, 1 mM MgCl 2 , 1 mM EGTA, 0.5 mM CHAPS, 10% glycerol, and 5 mM NaF) or AMPK lysis buffer (MacIver et al., 2011) supplemented with protease and phosphatase inhibitors (Roche), DTT (1 mg/ml), and benzamidine (1 mg/ml). Cleared lysates were resolved by SDS-PAGE, transferred to nitrocellulose, and incubated with primary antibodies. Primary antibodies to AMPK (pT172-specific and total), AMPKa2, ACC (pS79 and total), p70 S6 kinase (pT389-specific and total), S6 ribosomal protein (pS235/236-specific and total), 4E-BP1 (pT37/ 46-specific and total), LDHA, PDK1, Aldolase, and actin were obtained from Cell Signaling Technology. Anti-HIF-1a antibodies were from Cayman Biomedical.
Quantitative Real-Time PCR Total mRNA was isolated from cells with Trizol, and complementary DNA (cDNA) was synthesized from 100 ng total RNA with the Superscript VILO cDNA Synthesis Kit (Invitrogen). Quantitative PCR was performed with SYBR Green qPCR SuperMix (Invitrogen) and an Mx3005 qPCR machine (Agilent Technologies) with primers against aldoA, ldha, pdk1, hif1a, and actin. All samples were normalized to b-actin mRNA levels. Primer sequences are listed in Table S1 .
Metabolic Assays
Respirometry (OCR) and the extracellular acidification rate (ECAR) of cells were measured with an XF24 Extracellular Flux Analyzer (Seahorse Bioscience). In brief, cells were plated at 5 3 10 4 /well in 625 ml nonbuffered Dulbecco's modified Eagle's medium containing 25 mM glucose and 2 mM glutamine. Cells were incubated in a CO 2 -free incubator at 37 C for 1 hr to allow for temperature and pH equilibration prior to loading into the XF24 apparatus. XF assays consisted of sequential mix (3 min), pause (3 min), and measurement (5 min) cycles, allowing for determination of OCR/ECAR every 10 min. Glucose consumption and lactate production were determined via enzymatic assays described previously (Buzzai et al., 2007) . Glucose-derived lipid biosynthesis was determined by culturing of cells in medium containing 14 C-glucose for 3 days, and extracted lipids with a 1:1:1 Water/Methanol/ Chloroform extraction procedure (Mullen et al., 2012) . After extraction, the organic layer was isolated, dried via N 2 stream, resuspended in methanol, and incorporated radioactivity measured with a MicroBeta Liquid Scintillation Counter (Perkin Elmer).
Analysis of Metabolites by NMR and GC-MS
Metabolites from tissue culture cells were extracted as described previously . In brief, cells (2-5 3 10 6 /10 cm dish) were washed three times with ice-cold 0.9% saline solution. Cells were lysed with ice-cold 80% methanol followed by sonication (Diagenode Bioruptor), and extracts were dried by vacuum centrifugation. For NMR analysis, cell extracts were resuspended in 220 ml 2 H 2 O containing 0.2 mM 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS), 0.1 mM difluorotrimethylsilanylphosphonic acid (DFTMP), and 0.01 mM sodium azide. NMR data collection was performed at the Qué bec/Eastern Canada High Field NMR Facility on a 500 MHz Inova NMR system (Agilent Technologies) equipped with an HCN cryogenically cooled probe operating at 25 K. Metabolite chemical shift assignments were confirmed by total correlation spectroscopy, and targeted metabolites were profiled with a 500 MHz metabolite library from Chenomx. For GC-MS analysis, dried samples were resuspended in 30 ml anhydrous pyridine and added to GC-MS autoinjector vials containing 70 ml N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA) derivatization reagent. The samples were incubated at 70 C for 1 hr, after which aliquots of 1 ml were injected for analysis. GC-MS data were collected on an Agilent 5975C series GC/MSD system (Agilent Technologies) operating in election ionization mode (70 eV) and selected ion monitoring. Quantified metabolites were normalized relative to protein content (mg).
Statistical Analysis
Statistics were determined with a paired Student's t test, ANOVA, or log-rank (Mantel-Cox) test with Prism software (GraphPad). Data are calculated as the mean ± SEM unless otherwise indicated. Statistical significance is represented in figures by *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
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